Compare Tango Therapeutics Inc. (TNGX) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs United Microelectronics Corp — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B), while United Microelectronics Corp trades at $20.48 (market cap $55.41B). The key difference: United Microelectronics Corp is far larger — about 14.8× Tango Therapeutics Inc.'s market cap, and United Microelectronics Corp pays a 1.87% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and United Microelectronics Corp for 42 Days on average.
| TNGX | UMC | |
|---|---|---|
Market Cap | $3.74B | $55.41B |
Volume | 3,438,781 | 12,773,662 |
Sector | Health | Technology |
52-Week High | $32.90 | $28.02 |
52-Week Low | $7.50 | $7.02 |
Typical Hold Time | 0 Days | 42 Days |
Enterprise Value | $2.76B | $52.51B |
Dividend Yield | — | 1.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
UMC trades at $22.39, down 0.71% on the day, with a bullish technical signal despite recent volatility. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.54 significantly exceeding the $0.16 forecast. Revenue is projected to grow to $250.7 billion in 2026, with a net income margin rebounding to 32.75%. Cash flow trends show improving operational performance, with net cash flow turning positive in 2025 at $5.66 billion.
The outlook is positive given strong earnings momentum and AI-driven demand, but risks include competitive pressures and sensitivity to semiconductor cycles. Analyst sentiment is mixed with a Hold consensus, though some upgrades to Strong Buy highlight growth potential. The stock's valuation multiples suggest room for appreciation if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
